Free Trial

BioNTech (BNTX) Stock Forecast & Price Target

BioNTech logo
$109.26 -2.40 (-2.15%)
Closing price 04:00 PM Eastern
Extended Trading
$109.32 +0.06 (+0.05%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
13

Based on 17 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 4 have given a hold rating, and 13 have given a buy rating for BNTX.

Consensus Price Target

$135.91
24.39% Upside
According to the 17 analysts' twelve-month price targets for BioNTech, the average price target is $135.91. The highest price target for BNTX is $171.44, while the lowest price target for BNTX is $110.00. The average price target represents a forecasted upside of 24.39% from the current price of $109.26.
Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

Sign Up

BNTX Analyst Ratings Over Time

TypeCurrent Forecast
8/11/24 to 8/11/25
1 Month Ago
7/12/24 to 7/12/25
3 Months Ago
5/13/24 to 5/13/25
1 Year Ago
8/12/23 to 8/11/24
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
14 Buy rating(s)
5 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$135.91$137.91$142.73$109.00
Forecasted Upside24.39% Upside22.17% Upside51.04% Upside34.90% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioNTech Stock vs. The Competition

TypeBioNTechMedical CompaniesS&P 500
Consensus Rating Score
2.76
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside24.76% Upside12,604.25% Upside14.27% Upside
News Sentiment Rating
Neutral News

See Recent BNTX News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/5/2025Bank of America
4 of 5 stars
Tazeen Ahmad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$126.00 ➝ $134.00+21.78%
8/5/2025Wells Fargo & Company
3 of 5 stars
Mohit Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetOverweight ➝ Overweight$170.00 ➝ $150.00+36.32%
7/10/2025Morgan Stanley
3 of 5 stars
Terence Flynn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$132.00 ➝ $133.00+18.45%
6/25/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robert Burns
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$138.00+31.32%
6/3/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Asthika Goonewardene
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$151.00 ➝ $155.00+33.39%
6/2/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Daina Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$112.00+2.47%
5/29/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Asad Haider
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Neutral$110.00+12.79%
5/22/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jessica Fye
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$120.00 ➝ $116.00+17.24%
5/6/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Meacham
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$145.00 ➝ $140.00+38.48%
3/11/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
John Newman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$171.44 ➝ $171.44+65.58%
3/11/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Etzer Darout
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$130.00 ➝ $143.00+35.74%
11/19/2024Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
H. Gillis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$130.00+27.61%
11/19/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Kasimov
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeIn-Line ➝ Outperform$110.00 ➝ $125.00+22.71%
11/5/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$132.00 ➝ $122.00+10.28%
10/7/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$97.00 ➝ $136.00+10.88%
9/19/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$95.00 ➝ $150.00+33.87%
9/18/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$97.00 ➝ $131.00+5.04%
9/17/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$96.00 ➝ $150.00+21.49%
8/2/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
1/5/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:28 PM ET.


Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, August 8, 2025. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in BioNTech SE:

  • The current stock price is around $112.89, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high of $131.49.
  • Recent institutional investments have shown significant increases, with firms like Invesco Ltd. boosting their stake by over 600%, indicating strong confidence in the company's future performance.
  • BioNTech SE has a market capitalization of approximately $27.14 billion, reflecting its substantial size and stability in the biotechnology sector.
  • The company has received a "Moderate Buy" consensus rating from analysts, with a target price of around $135.91, suggesting potential for price appreciation.
  • BioNTech SE is actively involved in developing immunotherapies for cancer and infectious diseases, positioning itself in a growing market with high demand for innovative treatments.

BioNTech
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in BioNTech SE for these reasons:

  • The company has a negative price-to-earnings (PE) ratio of -33.20, which may indicate that it is currently unprofitable, raising concerns about its financial health.
  • Despite recent gains, the stock has experienced volatility, as evidenced by its beta of 1.29, suggesting that it may be more volatile than the overall market.
  • Only 15.52% of the stock is owned by institutional investors and hedge funds, which may imply a lack of widespread confidence among larger investors.
  • BioNTech SE's stock has a relatively high debt-to-equity ratio of 0.01, indicating low leverage, but this could also suggest limited growth potential through debt financing.
  • The company faces intense competition in the biotechnology field, which could impact its market share and profitability in the long term.

BNTX Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $135.91, with a high forecast of $171.44 and a low forecast of $110.00.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BNTX shares.

According to analysts, BioNTech's stock has a predicted upside of 24.39% based on their 12-month stock forecasts.

Analysts like BioNTech less than other "medical" companies. The consensus rating score for BioNTech is 2.76 while the average consensus rating score for "medical" companies is 2.81. Learn more on how BNTX compares to other companies.


This page (NASDAQ:BNTX) was last updated on 8/11/2025 by MarketBeat.com Staff
From Our Partners